News from Holden

Innovation Research

Musculoskeletal Tumor Registry collects QoL data after surgery in sarcoma

Benjamin J. Miller, MD, MS, discusses the creation of the Musculoskeletal Tumor Registry and how it is poised to make progress in the orthopedic oncology field with OncLive.


Work led by team at University of Iowa Holden Comprehensive Cancer Center enables greater access to targeted diagnosis and treatment of rare cancer

People with a rare cancer will have greater access to a drug enabling targeted diagnosis and treatment, thanks to work led by a team of researchers at University of Iowa Health Care’s PET Imaging Center.


Holden oncologist Muhammad Furqan, MD, receives NCI award for dedication to lung cancer clinical research

Furqan is one of eight recipients nationwide of the Cancer Clinical Investigator Team Leadership Award for outstanding work leading clinical trials.


Better incentives, infrastructure key to unlocking collaboration

True collaboration should be embedded in the practice of medicine. It should be baked in, a given, something we don’t need to write columns on.


When he ran out of options, Kent found the kidney cancer treatment he needed in a clinical trial

Tumors that had spread to Kent’s lungs were eliminated by a new immunotherapy offered in a clinical trial at Holden Comprehensive Cancer Center.


Holden Comprehensive Cancer Center opens new infusion suite, expanding cancer care for Iowans

University of Iowa Holden Comprehensive Cancer Center is opening a new infusion suite that will expand access to advanced cancer care for Iowans and patients from across the region.


Radioactive seed localization guides surgeons to exact location of small tumors.

Surgeons and radiologists with Holden Comprehensive Cancer Center are now using a less-invasive tool to localize breast cancers and other abnormalities that may be too small to feel.


Holden is one of three U.S. centers offering the latest radiation therapy technology.

The UI Department of Radiation Oncology this month began using a just-approved radiation therapy device that combines state-of-the-art imaging and radiation targeting. Holden Comprehensive Cancer Center is only the third center in the country offering this technology.